Canaccord Genuity Maintains Buy on Viking Therapeutics, Raises Price Target to $114

Benzinga Newsdesk www.benzinga.com Positive 84.3%

Neg 0% Neu 0% Pos 84.3%

Canaccord Genuity analyst Edward Nash maintains Viking Therapeutics (NASDAQ:VKTX) with a Buy and raises the price target from $107 to $114.